H.R. 586

119th Congress

In Committee

Vietnam Veterans Liver Fluke Cancer Study Act

Sponsored byRepublican:Rep. LaLota, Nick [R-NY-1]NY· Introduced 21 January 2025
Open on Congress.gov

8

Cosponsors

13

Actions

0

Amendments

2

Committees

—

Since introduced

Introduced
Committee
Passed Chamber
Passed Both
Enacted
Step 1 of 0
Latest action

Received in the Senate and Read twice and referred to the Committee on Veterans' Affairs.

8 April 2025·1 year ago

Summary

Introduced in House · Updated 3 March 2025

Vietnam Veterans Liver Fluke Cancer Study Act

This bill requires the Department of Veterans Affairs (VA) to conduct an epidemiological study and report on the prevalence of cholangiocarcinoma (bile duct cancer) in veterans who served in the Vietnam theater of operations during the Vietnam era. The study must identify the rate of incidence of cholangiocarcinoma in such veterans and in U.S. residents.

The bill also requires the VA to track and report on the prevalence of cholangiocarcinoma using the Veterans Affairs Central Cancer Registry. Additionally, the VA must periodically submit follow-up reports to Congress regarding the epidemiological study and information collected from the cancer registry regarding the prevalence of bile duct cancer.

Timeline

13 actions

  1. Received in the Senate and Read twice and referred to the Committee on Veterans' Affairs.

    8 April 2025 · IntroReferral

  2. DEBATE - The House proceeded with forty minutes of debate on H.R. 586.

    7 April 2025 · Floor

  3. Considered under suspension of the rules. (consideration: CR H1435-1437)

    7 April 2025 · Floor

  4. At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.

    7 April 2025 · Floor

  5. Considered as unfinished business. (consideration: CR H1441-1442)

    7 April 2025 · Floor

  6. Mr. Bost moved to suspend the rules and pass the bill, as amended.

    7 April 2025 · Floor

  7. On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 411 - 0 (Roll no. 89). (text: CR H1435-1436)

    7 April 2025 · Floor

  8. Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 411 - 0 (Roll no. 89). (text: CR H1435-1436: 1)

    7 April 2025 · Floor

  9. Motion to reconsider laid on the table Agreed to without objection.

    7 April 2025 · Floor

  10. Referred to the Subcommittee on Health.

    25 February 2025 · Committee

  11. Referred to the House Committee on Veterans' Affairs.

    21 January 2025 · IntroReferral

  12. Introduced in House

    21 January 2025 · IntroReferral

  13. Introduced in House

    21 January 2025 · IntroReferral

Sponsorship

8 cosponsors

Sponsor

Republican:Rep. LaLota, Nick [R-NY-1]NY

Cosponsors

  • Democrat563%
  • Republican338%

Classification

Policy area

Armed Forces and National Security

Legislative subjects

AsiaCancerConflicts and warsCongressional oversightGovernment studies and investigationsHealth information and medical recordsMedical researchVeterans' medical careVietnam

Committees

2

  • Veterans' Affairs Committee

    House · Standing

    • Referred To21 Jan 2025

    • Health Subcommittee

      • Referred to25 Feb 2025

  • Veterans' Affairs Committee

    Senate · Standing

    • Referred To8 Apr 2025

Cosponsor momentum

Cumulative over time

Cosponsors grew from 5 on 21 January 2025 to 8 on 7 April 2025.

Pelosi Tracker
Follow on XJoin our Discord
PoliticiansBillsPortfoliosPricingAboutLegalTerms of ServicePrivacy Policy
Français
© 2026 - All rights reserved. Powered by Vantara Labs
This website is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office, or her representatives. Any use of her name is solely for the purpose of discussing publicly available information.The information provided on this website is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.